TET2 and acute myeloid leukemia: MDS cases with TET2 mutation had a shorter period of time for progression to AML (HR = 7.81; 95% CI: 2.08–29.31) and tended to show an inferior survival in cases included in the very high-risk group of IPSS-R (HR = 2.02; 95% CI = 0.77–5.36) [63].